FDA issues second CRL for tabelecleucel in EBV+ PTLD, a decision Atara calls a reversal on trial design
The FDA's second rejection of Atara's allogeneic T-cell therapy found the ALLELE trial no longer adequate for accelerated approval, a position Atara called a reversal
